Lyell Immunopharma has entered into a Securities Purchase Agreement with institutional investors to raise approximately $80 million in gross proceeds through a private placement of its common stock. The transaction is expected to close on or about November 4, 2026.
Key Details
- Transaction: Sale of 7,428,040 shares of common stock at a purchase price of $10.77 per share.
- Gross Proceeds: The company expects to receive approximately $80.0 million before expenses.
- Timeline: The private placement was agreed upon on November 3, 2026, and is scheduled to close on November 4, 2026, subject to customary closing conditions.
- Registration Rights: Lyell has agreed to file a registration statement with the SEC within 30 days of closing to register the shares for resale by the investors.